PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 18765391-10 2008 Trimetazidine decreased insulin resistance (glucose: 5.9+/-0.7 versus 5.5+/-0.6 mmol/L, P=0.047; insulin: 10+/-6.9 versus 7.6+/-3.6 mU/L, P=0.031; homeostasis model assessment index: 2.75+/-2.28 versus 1.89+/-1.06, P=0.027). Trimetazidine 0-13 insulin Homo sapiens 24-31 18765391-10 2008 Trimetazidine decreased insulin resistance (glucose: 5.9+/-0.7 versus 5.5+/-0.6 mmol/L, P=0.047; insulin: 10+/-6.9 versus 7.6+/-3.6 mU/L, P=0.031; homeostasis model assessment index: 2.75+/-2.28 versus 1.89+/-1.06, P=0.027). Trimetazidine 0-13 insulin Homo sapiens 97-104 18765391-15 2008 Trimetazidine improved whole-body insulin sensitivity and glucose control in these insulin-resistant idiopathic dilated cardiomyopathy patients, thus hypothetically countering the myocardial damage of insulin resistance. Trimetazidine 0-13 insulin Homo sapiens 34-41 18765391-15 2008 Trimetazidine improved whole-body insulin sensitivity and glucose control in these insulin-resistant idiopathic dilated cardiomyopathy patients, thus hypothetically countering the myocardial damage of insulin resistance. Trimetazidine 0-13 insulin Homo sapiens 83-90 16174656-4 2006 Compared with placebo, trimetazidine induced 1) an increase in insulin-induced forearm glucose uptake and glucose oxidation accompanied by a reduction in forearm lipid oxidation and citrate release and 2) a decrease of endothelin-1 release paralleled by a significant increase in forearm cGMP release. Trimetazidine 23-36 insulin Homo sapiens 63-70 16503536-1 2006 OBJECTIVE: To evaluate the efficacy of trimetazidine on insulin resistance in patients with coronary heart disease (CHD). Trimetazidine 39-52 insulin Homo sapiens 56-63 16503536-5 2006 After 8 weeks" trimetazidine therapy, the fasting insulin and that at 2 h after oral glucose were decreased (P<0.01), and the insulin sensitivity index was improved (P<0.01). Trimetazidine 15-28 insulin Homo sapiens 50-57 16503536-5 2006 After 8 weeks" trimetazidine therapy, the fasting insulin and that at 2 h after oral glucose were decreased (P<0.01), and the insulin sensitivity index was improved (P<0.01). Trimetazidine 15-28 insulin Homo sapiens 129-136 16503536-6 2006 CONCLUSION: Trimetazidine may produce obvious therapeutic effect on insulin resistance in CHD patients. Trimetazidine 12-25 insulin Homo sapiens 68-75 16174656-6 2006 In conclusion, for the first time, we demonstrated that insulin-induced forearm glucose oxidation and forearm cGMP release were increased whereas forearm endothelin-1 release was decreased during trimetazidine treatment. Trimetazidine 196-209 insulin Homo sapiens 56-63 35365489-0 2022 Trimetazidine and exercise offer analogous improvements to the skeletal muscle insulin resistance of mice through Nrf2 signaling. Trimetazidine 0-13 insulin Homo sapiens 79-86 35365489-8 2022 RESULTS: In vivo, TMZ and exercise decreased the blood glucose and insulin levels and homeostasis model assessment of IR index, increased skeletal muscle insulin signaling-related protein ratios of p-IRS1/IRS1 and p-AKT/AKT, and both interventions activated Nrf2 signaling and reduced oxidative stress production in HFD mice. Trimetazidine 18-21 insulin Homo sapiens 67-74 35365489-8 2022 RESULTS: In vivo, TMZ and exercise decreased the blood glucose and insulin levels and homeostasis model assessment of IR index, increased skeletal muscle insulin signaling-related protein ratios of p-IRS1/IRS1 and p-AKT/AKT, and both interventions activated Nrf2 signaling and reduced oxidative stress production in HFD mice. Trimetazidine 18-21 insulin Homo sapiens 154-161 35365489-9 2022 In vitro, TMZ reduced the oxidative stress reaction, increased the ratios of p-AKT/AKT and p-IRS1/IRS1, and attenuated the insulin stimulation of PA-induced glucose uptake. Trimetazidine 10-13 insulin Homo sapiens 123-130